JP2019520061A - Ｔ細胞の増殖 - Google Patents

Ｔ細胞の増殖 Download PDF

Info

Publication number
JP2019520061A
JP2019520061A JP2018562017A JP2018562017A JP2019520061A JP 2019520061 A JP2019520061 A JP 2019520061A JP 2018562017 A JP2018562017 A JP 2018562017A JP 2018562017 A JP2018562017 A JP 2018562017A JP 2019520061 A JP2019520061 A JP 2019520061A
Authority
JP
Japan
Prior art keywords
cells
medium
culture
population
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520061A5 (enExample
Inventor
ワン，ピーター
ウー，チュンシャオ
Original Assignee
テッサ・セラピューティクス・プライベート・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テッサ・セラピューティクス・プライベート・リミテッド filed Critical テッサ・セラピューティクス・プライベート・リミテッド
Publication of JP2019520061A publication Critical patent/JP2019520061A/ja
Publication of JP2019520061A5 publication Critical patent/JP2019520061A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018562017A 2016-05-24 2016-10-25 Ｔ細胞の増殖 Pending JP2019520061A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340605P 2016-05-24 2016-05-24
US62/340,605 2016-05-24
US15/290,230 US10052372B2 (en) 2016-05-24 2016-10-11 T cell expansion
US15/290,230 2016-10-11
PCT/EP2016/075644 WO2017202478A1 (en) 2016-05-24 2016-10-25 T cell expansion

Publications (2)

Publication Number Publication Date
JP2019520061A true JP2019520061A (ja) 2019-07-18
JP2019520061A5 JP2019520061A5 (enExample) 2019-11-14

Family

ID=57886334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562017A Pending JP2019520061A (ja) 2016-05-24 2016-10-25 Ｔ細胞の増殖

Country Status (12)

Country Link
US (2) US10052372B2 (enExample)
EP (1) EP3265555B1 (enExample)
JP (1) JP2019520061A (enExample)
KR (1) KR20190013831A (enExample)
CN (1) CN109563483A (enExample)
DK (1) DK3265555T3 (enExample)
ES (1) ES2742215T3 (enExample)
HK (1) HK1250378B (enExample)
PT (1) PT3265555T (enExample)
SG (1) SG11201810471YA (enExample)
TW (1) TWI660970B (enExample)
WO (1) WO2017202478A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064884T2 (hu) * 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelések
WO2017192717A1 (en) 2016-05-05 2017-11-09 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
EP3920616B1 (en) * 2017-05-06 2023-03-22 LG Electronics Inc. D2d operation method by terminal in wireless communication system and terminal using said method
WO2019118902A2 (en) * 2017-12-15 2019-06-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting t cell exhaustion
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
WO2020068840A1 (en) 2018-09-24 2020-04-02 Southwest Research Institute Three-dimensional bioreactors
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
WO2022197933A1 (en) 2021-03-18 2022-09-22 The Broad Institute, Inc. Compositions and methods for characterizing lymphoma and related conditions
EP4330379A2 (en) 2021-04-27 2024-03-06 Baylor College of Medicine Virus-specific immune cells expressing chimeric antigen receptors
KR20250024750A (ko) 2022-04-13 2025-02-19 티크바 알로셀 피티이. 엘티디. 치료용 t 세포 산물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133297A1 (ja) * 2012-03-07 2013-09-12 国立大学法人富山大学 T細胞の刺激方法およびその利用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
WO1999025812A1 (en) 1997-11-14 1999-05-27 Hemosol Inc. Method for the production and use of dendritic cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
JP2013512694A (ja) * 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
SG11201404677TA (en) * 2011-12-12 2014-11-27 Cell Medica Ltd Process of expanding t cells
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133297A1 (ja) * 2012-03-07 2013-09-12 国立大学法人富山大学 T細胞の刺激方法およびその利用
EP2824182A1 (en) * 2012-03-07 2015-01-14 National University Corporation University Of Toyama Method for stimulating t cell and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, JPN6020048601, 1999, pages 1925 - 1932, ISSN: 0004409164 *

Also Published As

Publication number Publication date
DK3265555T3 (da) 2019-08-12
US20190269768A1 (en) 2019-09-05
CN109563483A (zh) 2019-04-02
HK1250378B (en) 2020-05-08
US20170028042A1 (en) 2017-02-02
US10052372B2 (en) 2018-08-21
TWI660970B (zh) 2019-06-01
SG11201810471YA (en) 2018-12-28
TW201741330A (zh) 2017-12-01
KR20190013831A (ko) 2019-02-11
PT3265555T (pt) 2019-09-04
EP3265555A1 (en) 2018-01-10
WO2017202478A1 (en) 2017-11-30
ES2742215T3 (es) 2020-02-13
EP3265555B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
EP3265555B1 (en) T cell expansion
HK1250378A1 (en) T cell expansion
TWI780069B (zh) 用於病毒專一性t細胞之活化及增生的平台
US20200172864A1 (en) T Cell Expansion Method
US10577586B2 (en) Compositions and methods for modulating an immune response
Wang et al. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway
EP3666888A2 (en) Method for activating t cells for cancer treatment
JP5016489B2 (ja) 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
CN101258238A (zh) 抗原呈递细胞的活化处理方法
CN110575537A (zh) Dc疫苗和nkg2a拮抗剂的组合物及在抗乳腺癌或肝癌中的应用
JP2025106402A (ja) がん治療のためのｔ細胞の活性化方法
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
US20090041792A1 (en) Dendritic cells, uses therefor, and vaccines and methods comprising the same
JP2018531618A (ja) ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成
CN115461063A (zh) 使用同种异体肿瘤特异性cd4+t细胞输注的癌症免疫疗法
TWI458485B (zh) 毒殺型樹突細胞群組用於製備藥物的用途及包含其之醫藥組合物
CN114949189A (zh) 纳米肿瘤特异抗原与发生icd的肿瘤细胞联合作为制备治疗性肿瘤疫苗的应用
CN119390814B (zh) 一种t细胞受体及其制备方法和用途
CN1230204C (zh) 通过继承性转运抗原特异性的细胞毒t细胞建立的免疫调节方法
CN118086212A (zh) 新冠病毒表位多肽致敏的树突状细胞及其应用
CN117778330A (zh) 新冠病毒特异性t细胞及其应用
CN117904054A (zh) 新冠病毒SARS-CoV-2特异性T细胞及其应用
Jalili et al. Sayahinouri M, Dehghani Ghorbi M, Roshandel E, Aghdami N. Virus-Specific T cells: Promising Adoptive T Cell Therapy against Infectious Diseases following Hematopoietic
Spence Investigating Antigen Presentation by Inactivated Lymphocytic Choriomeningitis Virus and by Baculovirus Encoding the LCMV-Nucleoprotein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210701